Thermo Fisher Scientific Inc (TMO) Position Increased by Summit Global Investments

Summit Global Investments boosted its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 28.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,530 shares of the medical research company’s stock after purchasing an additional 780 shares during the quarter. Summit Global Investments’ holdings in Thermo Fisher Scientific were worth $616,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Sharkey Howes & Javer lifted its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares during the period. Beacon Trust Co. lifted its stake in Thermo Fisher Scientific by 0.6% during the 1st quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock valued at $341,000 after acquiring an additional 12 shares during the period. Reinhart Partners Inc. lifted its stake in Thermo Fisher Scientific by 0.6% during the 2nd quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 20 shares during the period. Azimuth Capital Management LLC lifted its stake in Thermo Fisher Scientific by 0.8% during the 1st quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after acquiring an additional 25 shares during the period. Finally, Bienville Capital Management LLC lifted its stake in Thermo Fisher Scientific by 1.6% during the 2nd quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock valued at $295,000 after acquiring an additional 27 shares during the period. 83.32% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Inc (TMO) opened at 188.77 on Wednesday. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The company has a market cap of $73.64 billion, a PE ratio of 32.89 and a beta of 1.05. The stock has a 50 day moving average of $189.61 and a 200 day moving average of $175.55.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/10/18/thermo-fisher-scientific-inc-tmo-position-increased-by-summit-global-investments.html.

Several equities analysts have issued reports on TMO shares. Leerink Swann upped their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price on the stock in a research note on Thursday, September 21st. Bank of America Corporation restated a “buy” rating and set a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Finally, BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $203.64.

In related news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the sale, the vice president now owns 19,751 shares in the company, valued at $3,657,490.18. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares in the company, valued at approximately $6,702,635.58. The disclos

A number of other hedge funds have also recently made changes to their positions in the stock. Sharkey Howes & Javer lifted its stake in Thermo Fisher Scientific by 1.0% during the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares during the period. Beacon Trust Co. lifted its stake in Thermo Fisher Scientific by 0.6% during the 1st quarter. Beacon Trust Co. now owns 2,159 shares of the medical research company’s stock valued at $341,000 after acquiring an additional 12 shares during the period. Reinhart Partners Inc. lifted its stake in Thermo Fisher Scientific by 0.6% during the 2nd quarter. Reinhart Partners Inc. now owns 3,430 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 20 shares during the period. Azimuth Capital Management LLC lifted its stake in Thermo Fisher Scientific by 0.8% during the 1st quarter. Azimuth Capital Management LLC now owns 3,210 shares of the medical research company’s stock valued at $493,000 after acquiring an additional 25 shares during the period. Finally, Bienville Capital Management LLC lifted its stake in Thermo Fisher Scientific by 1.6% during the 2nd quarter. Bienville Capital Management LLC now owns 1,687 shares of the medical research company’s stock valued at $295,000 after acquiring an additional 27 shares during the period. 83.32% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Inc (TMO) opened at 188.77 on Wednesday. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30. The company has a market cap of $73.64 billion, a PE ratio of 32.89 and a beta of 1.05. The stock has a 50 day moving average of $189.61 and a 200 day moving average of $175.55.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/10/18/thermo-fisher-scientific-inc-tmo-position-increased-by-summit-global-investments.html.

Several equities analysts have issued reports on TMO shares. Leerink Swann upped their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price on the stock in a research note on Thursday, September 21st. Bank of America Corporation restated a “buy” rating and set a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cowen and Company restated an “outperform” rating and set a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Finally, BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $203.64.

In related news, VP Peter E. Hornstra sold 3,894 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total value of $721,090.92. Following the sale, the vice president now owns 19,751 shares in the company, valued at $3,657,490.18. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jim P. Manzi sold 11,318 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares in the company, valued at approximately $6,702,635.58. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,738 shares of company stock worth $9,302,112. 0.49% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply